Compare Avalanche Treasury Corporation Class A Common Stock (AVAT) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avalanche Treasury Corporation Class A Common Stock vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Avalanche Treasury Corporation Class A Common Stock trades at $0.52 (market cap $21.65M), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $300.5 (market cap $8.04B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 371.4× Avalanche Treasury Corporation Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Avalanche Treasury Corporation Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| AVAT | BIO | |
|---|---|---|
Market Cap | $21.65M | $8.04B |
Sector | Financials | Health |
52-Week High | $10.75 | $339.75 |
52-Week Low | $0.51 | $241.71 |
Enterprise Value | $21.65M | $7.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVAT stock trades at $0.506, down 6.3% today, with a bearish technical signal from moving averages. The company shows mixed fundamentals with a low P/E of 12 and P/B of 0.4, but negative cash flow from operations at -$930,710 in 2025. Recent Nasdaq listing news highlights its role as an operating company and digital asset treasury focused on capital allocation across the Avalanche economy.
The outlook remains cautious due to negative operational cash flow and bearish technical indicators. Investment opportunity lies in the discounted valuation multiples, while risks include sustained cash burn and competitive pressures in treasury management services. Market sentiment is neutral with recent media coverage of the Nasdaq debut.
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avalanche Treasury Corporation Class A Common Stock
Avalanche Treasury Corp operates as a digital asset treasury company focused on holding and managing digital asset investments. The company was founded on September 22, 2025, and is headquartered in New York, NY.
Read more on AVAT →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
